187 related articles for article (PubMed ID: 34254366)
1. Early aspirin use, allograft rejection, and cardiac allograft vasculopathy in heart transplantation.
Bergmark BA; Zelniker TA; Kim M; Mehra MR; Stewart GC; Page DS; Woodcome EL; Givertz MM
Clin Transplant; 2021 Oct; 35(10):e14424. PubMed ID: 34254366
[TBL] [Abstract][Full Text] [Related]
2. Early aspirin use and the development of cardiac allograft vasculopathy.
Kim M; Bergmark BA; Zelniker TA; Mehra MR; Stewart GC; Page DS; Woodcome EL; Smallwood JA; Gabardi S; Givertz MM
J Heart Lung Transplant; 2017 Dec; 36(12):1344-1349. PubMed ID: 28781013
[TBL] [Abstract][Full Text] [Related]
3. Early aspirin use and the development of cardiac allograft vasculopathy in pediatric heart transplant recipients: A pediatric heart transplant society analysis.
D'Addese L; Cantor RS; Koehl D; Reardon L; Ameduri R; Bock M; Morrison A; White S; Wisotzkey B; Kirklin JK; Godown J
J Heart Lung Transplant; 2023 Jan; 42(1):115-123. PubMed ID: 36328858
[TBL] [Abstract][Full Text] [Related]
4. The effect of timing and graft dysfunction on survival and cardiac allograft vasculopathy in antibody-mediated rejection.
Clerkin KJ; Restaino SW; Zorn E; Vasilescu ER; Marboe CC; Mancini DM
J Heart Lung Transplant; 2016 Sep; 35(9):1059-66. PubMed ID: 27423693
[TBL] [Abstract][Full Text] [Related]
5. Early aspirin initiation following heart transplantation is associated with reduced risk of allograft vasculopathy during long-term follow-up.
Peled Y; Lavee J; Raichlin E; Katz M; Arad M; Kassif Y; Peled A; Asher E; Elian D; Har-Zahav Y; Shlomo N; Freimark D; Goldenberg I; Klempfner R
Clin Transplant; 2017 Dec; 31(12):. PubMed ID: 28990263
[TBL] [Abstract][Full Text] [Related]
6. Association of Aspirin Treatment With Cardiac Allograft Vasculopathy Progression and Adverse Outcomes After Heart Transplantation.
Asleh R; Briasoulis A; Smith B; Lopez C; Alnsasra H; Pereira NL; Edwards BS; Clavell AL; Stulak JM; Locker C; Kremers WK; Daly RC; Lerman A; Kushwaha SS
J Card Fail; 2021 May; 27(5):542-551. PubMed ID: 33962742
[TBL] [Abstract][Full Text] [Related]
7. Myocardial perfusion reserve and global longitudinal strain as potential markers of coronary allograft vasculopathy in late-stage orthotopic heart transplantation.
Narang A; Blair JE; Patel MB; Mor-Avi V; Fedson SE; Uriel N; Lang RM; Patel AR
Int J Cardiovasc Imaging; 2018 Oct; 34(10):1607-1617. PubMed ID: 29728952
[TBL] [Abstract][Full Text] [Related]
8. Platelet aggregation and response to aspirin therapy in cardiac allograft vasculopathy.
Bjerre KP; Clemmensen TS; Berg K; Poulsen SH; Hvas AM; Grove EL; Løgstrup BB; Jakobsen L; Thim T; Kristensen SD; Eiskjær H
J Heart Lung Transplant; 2020 Apr; 39(4):371-378. PubMed ID: 32067865
[TBL] [Abstract][Full Text] [Related]
9. Association of Clinical Rejection Versus Rejection on Protocol Biopsy With Cardiac Allograft Vasculopathy in Pediatric Heart Transplant Recipients.
Asimacopoulos EP; Garbern JC; Gauvreau K; Blume ED; Daly KP; Singh TP
Transplantation; 2020 Jan; 104(1):e31-e37. PubMed ID: 31568274
[TBL] [Abstract][Full Text] [Related]
10. Late onset antibody-mediated rejection and endothelial localization of vascular endothelial growth factor are associated with development of cardiac allograft vasculopathy.
Bayliss J; Bailey M; Leet A; Stein AN; Thomson NM; McLean CA
Transplantation; 2008 Oct; 86(7):991-7. PubMed ID: 18852667
[TBL] [Abstract][Full Text] [Related]
11. Routine C4d immunohistochemistry in cardiac allografts: Long-term outcomes.
Husain AN; Mirza KM; Fedson SE
J Heart Lung Transplant; 2017 Dec; 36(12):1329-1335. PubMed ID: 28988608
[TBL] [Abstract][Full Text] [Related]
12. Mild acute cellular rejection and development of cardiac allograft vasculopathy assessed by intravascular ultrasound and coronary angiography in heart transplant recipients-a SCHEDULE trial substudy.
Nelson LM; Andreassen AK; Arora S; Andersson B; Gude E; Eiskjaer H; Rådegran G; Dellgren G; Gullestad L; Gustafsson F
Transpl Int; 2020 May; 33(5):517-528. PubMed ID: 31958178
[TBL] [Abstract][Full Text] [Related]
13. Timing of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor initiation and allograft vasculopathy progression and outcomes in heart transplant recipients.
Asleh R; Briasoulis A; Pereira NL; Boilson BA; Edwards BS; Adigun R; Maltais S; Daly RC; Lerman A; Kushwaha SS
ESC Heart Fail; 2018 Dec; 5(6):1118-1129. PubMed ID: 30019530
[TBL] [Abstract][Full Text] [Related]
14. The effects of donor-specific antibody characteristics on cardiac allograft vasculopathy.
Wang M; Patel NJ; Zhang X; Kransdorf EP; Azarbal B; Kittleson MM; Czer LSC; Kobashigawa JA; Patel JK
Clin Transplant; 2021 Dec; 35(12):e14483. PubMed ID: 34546613
[TBL] [Abstract][Full Text] [Related]
15. Cardiac allograft vasculopathy: Incidence and predictors in a single-center cohort.
Picão S; Oliveira-Santos M; Batista M; Prieto D; Antunes MJ; Pego M; Matos V; Gonçalves L; Jorge E
Rev Port Cardiol (Engl Ed); 2020 Apr; 39(4):205-212. PubMed ID: 32471665
[TBL] [Abstract][Full Text] [Related]
16. C4d immunostaining is an independent predictor of cardiac allograft vasculopathy and death in heart transplant recipients.
Luk A; Alba AC; Butany J; Tinckam K; Delgado D; Ross HJ
Transpl Int; 2015 Jul; 28(7):857-63. PubMed ID: 25778989
[TBL] [Abstract][Full Text] [Related]
17. Computational Analysis of Routine Biopsies Improves Diagnosis and Prediction of Cardiac Allograft Vasculopathy.
Peyster EG; Janowczyk A; Swamidoss A; Kethireddy S; Feldman MD; Margulies KB
Circulation; 2022 May; 145(21):1563-1577. PubMed ID: 35405081
[TBL] [Abstract][Full Text] [Related]
18. Characterization of immune responses to cardiac self-antigens myosin and vimentin in human cardiac allograft recipients with antibody-mediated rejection and cardiac allograft vasculopathy.
Nath DS; Ilias Basha H; Tiriveedhi V; Alur C; Phelan D; Ewald GA; Moazami N; Mohanakumar T
J Heart Lung Transplant; 2010 Nov; 29(11):1277-85. PubMed ID: 20615726
[TBL] [Abstract][Full Text] [Related]
19. Progression of cardiac allograft vasculopathy assessed by serial three-vessel quantitative coronary angiography.
Zanchin C; Yamaji K; Rogge C; Lesche D; Zanchin T; Ueki Y; Windecker S; Mohacsi P; Räber L; Sigurdardottir V
PLoS One; 2018; 13(8):e0202950. PubMed ID: 30148864
[TBL] [Abstract][Full Text] [Related]
20. Association of acidic fibroblast growth factor and untreated low grade rejection with cardiac allograft vasculopathy.
Zhao XM; Citrin BS; Miller GG; Frist WH; Merrill WH; Fischell TA; Atkinson JB; Yeoh TK
Transplantation; 1995 Apr; 59(7):1005-10. PubMed ID: 7535956
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
